Kura Oncology Grants Stock Options to Three New Employees
What happened
Kura Oncology's Compensation Committee granted inducement awards consisting of nonstatutory stock options to three new employees on November 2, 2026. These options are part of the Company’s 2023 Inducement Option Plan, as amended. Each stock option has an exercise price of $9.79 per share and will vest over four years.
From manilatimes.net
Why it matters
The grant involves 55,500 shares of common stock, which is subject to Nasdaq Listing Rule 5635(c)(4). This action relates to Kura Oncology's compensation strategy for new hires.
From manilatimes.net
Who's involved
- Kura OncologyBiopharmaceutical company that granted stock options to new employees
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- NasdaqSpeculative
The grant of stock options could affect the market price of the Nasdaq-listed company.
Possible ripples
Who this could reach next, traced step by step from the reporting. Possibilities worth considering, not forecasts.Keep exploring
The entities involved
-
Kura Oncology
company in La Jolla, United States
Nothing else this week.
-
LinkedIn
American social networking website for people in professional occupations
- FDA
Related events
- Syndax Pharmaceuticals has FDA-approved therapies in its pipeline and uses LinkedIn for company communication.
- A company with FDA-approved therapies used LinkedIn for information and its board approved a stock award for CFO hiring.
- Pelthos Therapeutics Inc. followed another company on LinkedIn on November 1, 2026.
- Pelthos Therapeutics Inc. began using LinkedIn for investor outreach on July 1, 2026.
- University of Liberia is utilizing LinkedIn to provide updates regarding its campaigns.